Home
|
Sitemap
|
Contact Us
|
Login
About Us
About Us
Vision & Mission
Industry Overview
FAQ
Contact Us
PhAMA Members
Board of Directors
Membership Directory
Membership Details
AWARDS 2016
Winners 2016
PhAMA Awards 2016
Instructions
- MIRA Award
Online Form
- MIRA Award
Past Year Winners (2015)
Past Year Winners (2014)
Events
PhAMA Calender
Announcements
CSR Activities of Members
CSR Activities 1
CSR Activities 2
CSR Activities 3
Survanta Graduation Party: Hospital Taiping
Survanta Graduation Party: Hospital Selayang
Survanta: A Life of Promises
Reduce 10 Weight Management Program
CSR Activities 4
Launch of PhAMA Industry Factbook
1st National Bio-therapeutics Congress (Photos)
PhAMA Biosimilar Summit (22 November 2014)
PhAMA Dinner 2015 (Photos)
PhAMA Dinner 2017 (Photos)
Pharma Industry
PhAMA Publications
Code of Conduct -
Marketing Practices
Code of Conduct (Non Prescription)
PhAMA Industry Fact Book 2012
Building Greater Access to Innovative Medicines
Is Reference Pricing Right for Malaysia?
PhAMA Position Papers
Value Pricing for Improved Patient Access in Malaysia
PhAMA Position Papers on Intellectual Property
Training
PhAMA Code of Marketing Practices (20th Ed)
Programme Modules
Presentation Slide
Disease Awareness
Introduction
AIDS
Diabetics
Cancer
Cardiovascular
Mental Health
Obesity
Self-Medication
Resources
International Links
National Links
Government Hospitals
Private Hospitals
Doctors - MMA
Pharmacies & Pharmacists
Academy of Medicine Malaysia
National Specialist Register
MIMS Search Database
Announcements
Quick Search Article:
Category:
All
DCA letters
General News
MAB Letter
NPCB
There are
27 records
that matched your search criteria (sorted by :
Title DESC order
)
Date
Title
Category
14-Sep-2009
Caution Statement on “Possible Interaction between Clopidogrel and Proton Pump Inhibitors” required to be included in the product package insert for Clopidogrel
Bil (42) dlm. BPFK/PPP/01/03 dated 14th Sept 2009
DCA letters
13-Oct-2009
Caution Statement on “Increased Risk for Opportunistic Infections such as Activation of Latent Viral Infections Including BK Virus-Associated Nephropathy” required to be included in the product package insert for Immunosuppressant
Bil (44) dlm. BPFK/PPP/01/03 dated 13th October 2009
DCA letters
22-Jul-2010
Caution Statement on "Boxed warning" must include Propylthiouracil with "Severe Liver Injury"
Bil (55) dlm. BPFK/PPP/01/03 dated 22nd Jul 2010
DCA letters
23-Feb-2011
Briefing on 'Competition Act 2010'
by the Ms Shila Dorai Raj, Director of the Interim Competition Commission, MDTCC
General News
15-Sep-2009
Advertisement on Products for nicotine replacement therapy with MAB Approval
Bil (37) dlm KKM-55/205/001/02 Jld 5 dated 15th Sept 2009
MAB Letter
12-Nov-2009
8th List for BE Studies for Oral “Immediate Release” Generic Products
Bil (46) dlm. BPFK/PPP/01/03 dated 30th October 2009
DCA letters
24-Mar-2016
44th PhAMA Annual General Meeting 2016
Previous
|
1
| 2
21 - 27 of 27 results
Copyright © 2009 - 2018 Pharmaceutical Association of Malaysia (PhAMA). All Rights Reserved.
Powered by
CORNERSTONE CONTENT MANAGEMENT SYSTEM